Brian M. Johnson, MD CCRMC PBL 11/7/12

Slides:



Advertisements
Similar presentations
DEEP VEIN THROMBOSIS.
Advertisements

Venous thromboembolic diseases: Deep vein thrombosis
Venous thromboembolic diseases: Pulmonary embolism
Deep Vein Thrombosis (DVT) The Patient Journey
Investigations for PE and DVT, including sensitivity and specificity
Viral vents his frustration with.  What the d-dimer actually measures  Usual applications of d-dimer  Interesting applications of d-dimer  How to.
Medical Student Small Group Discussion Topics
Venous Thromboembolism: Risk Assessment and Prophylaxis
VTE Toolkit Chapter Five Venous Disease Coalition
Atiya Khalid GPST1 A & E;AGH. Defination: DVT is the formation of a thrombus (blood clot) in a deep vein, usually in the legs, which partially or completely.
Testing for DVT/PE Steve Kizer MD. Why do the strategies for testing for thromboembolic disease seem so difficult? Confusion as to the goals of treatment.
Treatment of Acute Pulmonary Embolism
Stephan Moll, MD University of North Carolina Chapel Hill, N.C. Dept. of Medicine, Heme-Onc Tel: Richmond 9/29/2006 Venous.
Bleeding and Thrombosis in Children Alice J. Cohen, M.D. Newark Beth Israel Medical Center.
Venous Thromboembolism
Deep Vein Thrombosis (DVT)
Deep vein thrombosis David Hughes. Pathophysiology normal deep pelvic/leg veins thrombus (red cells, fibrin) around valves propagation Virchow’s triad.
The DASH Study Patrick Leonberger MSIV BGSMC Nov 8, 2013.
Below the Knee DVT and Pregnancy Related Thrombosis Robert Lampman, MD Morning Report July 2009.
DPT 732 SPRING 2009 S. SCHERER Deep Vein Thrombosis.
Venous thromboembolism: how long to treat?
D-dimer in the Diagnosis of Pulmonary Embolism Cheryl Pollock PGY-3.
© Siemens All rights reserved. The Clinical Utility of D-dimer Assays Beth Phillips MT,SH (ASCP) Zone Technical Application Specialist Siemens Healthcare.
Deep vein thrombosis. Color duplex scan of DVT Venogram shows DVT.
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
Unprovoked DVT in a young patient
TURANDOT SAUL, M.D. SEPTEMBER 12TH, 2007 ST. LUKE’S ROOSEVELT HOSPITAL DEPARTMENT OF EMERGENCY MEDICINE Deep Venous Thrombosis.
DVT: Symptoms and work-up Sean Stoneking. DVT Epidemilogy Approximately 600,0000 new cases of DVT each year 50% in hospitalized patients or nursing home.
What is it? A deep vein thrombosis is a condition where the blood clots in a distal, deep vein A blood clot is considered a thrombosis as long as it is.
Extended Anticoagulation in VTE Geoffrey Barnes, MD Cardiovascular and Vascular Medicine University of Michigan, USA 1 st Qatar Conference on Safe Anticoagulation.
DR FAROOQ AHMAD RANA ASSISTANT PROFESSOR SURGERY
Thromboembolism IT training Presentation Midwifery update Marie Lewis.
What You Need to Know about Blood Clots. What You Need to Know About Blood Clots or Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
Prospective evaluation of Innovance D-dimer in the exclusion of venous thromboembolism [VTE]. Robert Gosselin, CLS Department of Clinical Pathology and.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?
Case Report Pneumology Dr. David Tran A&E, FVHospital Medical meeting September 28 th, 2011.
به نام خدا. دكتر محمد امامي فوق تخصص ريه عضو هيات علمي دانشگاه.
Venous Thromboembolism: Diagnosis and Managament
Deep Vein Thrombosis & Malignancy Department of Radiation Oncology Presented by Dr. Muhammad Zubaer Hussain Deep Vein Thrombosis & Malignancy Department.
71-year old male Admitted with worsening shortness of breath PMHx: Severe COPD, A.Fib, CHF/ischemic, PE On long term anticoagulation with Pradaxa 150.
Chapter Seven Venous Disease Coalition Long-Term Management of VTE VTE Toolkit.
DVT & PE: How early can I mobilize a patient ??
1. Statistics Objectives: 1.Try to differentiate between the P value and alpha value 2.When to perform a test 3.Limitations of different tests and how.
Risk assessment for VTE Dr Roopen Arya King’s College Hospital.
Risk Assessment for VTE. Which of the following best describes you?
Venous thromboembolism
Duration of Anticoagulation 5 Patients Categories 3. First Episode: 4. First Episode: 5.Recurrent DVT 2. First Episode: 1. First Episode: Transient risk.
PE Clinical Evaluation. Presenting Complaint Most common presenting complaint: dyspnoea Chest pain Syncope Cough Leg pain.
 Deep Vein Thrombosis Josh Vrona, Hunter Dolan, Erin McCann.
Deep vein thrombosis and pulmonary embolism.
Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing June 2012 NICE clinical guideline.
Diagnosis of Deep Vein Thrombosis Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis, 9th.
Venous Thromboembolism (VTE) Etiology, Prevention, Recognition, and Treatment 1.
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
Venous Thromboembolic Disease: The Role of Novel Anticoagulants Grant M. Greenberg MD, MA, MHSA.
Serial 2-Point Ultrasonography Plus D-Dimer vs Whole-LegColor-CodedDopplerUltrasonography for Diagnosing Suspected Symptomatic Deep Vein Thrombosis A Randomized.
Outpatient DVT assessment & treatment Daniel Gilada.
Diagnosis Recitation. The Dilemma At the conclusion of my “diagnosis” presentation during the recent IAPA meeting, a gentleman from the audience asked.
Accuracy and usefulness of a clinical prediction rule and D-dimer testing in excluding deep vein thrombosis in cancer patients Thrombosis Research (2008)
CRT 2012 Venous Disease.
the proximal femoral fracture patients
Diagnosis of venous thromboembolism
The Evaluation of Suspected Pulmonary Embolism
Evidence Based and Cost Effective Guideline for DVT Triage
Deep vein thrombosis outpatient pathway and ultrasound sensitivity
Venous Thromboembolism (VTE)
Calculate Well’s score for PE (BOX1)
Identifying Low-Risk Patients with Pulmonary Embolism Suitable For Outpatient Treatment A VERITY Registry Pilot Study N Scriven, T Farren, S Bacon, T.
Clinical case of a swollen limb Emphasis on diagnosis
Presentation transcript:

Brian M. Johnson, MD CCRMC PBL 11/7/12 Deep Vein Thrombosis Brian M. Johnson, MD CCRMC PBL 11/7/12

Case 1 Mrs. Z, a 44-year-old woman without significant PMH, presents for an urgent visit with left leg swelling of two days duration. She takes no medications and reports moderate leg pain but no chest pain, shortness of breath, or palpitations.

What is the differential diagnosis of unilateral leg swelling? DVT 2. Cellulitis 3. Baker’s cyst 4. Lymphedema 5. Fracture Post-thrombotic syndrome Venous insufficiency Scorpions? Or bee stings? Toxins Mass Trauma / Compartment syndrome

What are risk factors for DVT? Hospitalization Long-term immobility OCP Smoking Age Surgery Cancer CHF Renal disease Cirrhosis Pregnancy Anti-psychotics Thrombophilias Obesity Restrictive clothing Gender Lupus (and other autoimmune diseases) Sickle Cell

Case Continued… She reports that she has no family history of blood clots to her knowledge and that she is not pregnant. She denies any “warning signs” of cancer and is up to date on her cancer screening (mammogram, Pap smear; no colorectal cancer screening, but she denies family history of colorectal cancer so she is not yet due). She denies recent immobilization or trauma. Her exam is significant for a minimally swollen right calf. To ensure a reliable assessment of circumference, you mark off 10cm below each tibial tuberosity and measure the circumference at that level. You find that the right calf measures 1cm larger in circumference than the left. There is no edema or skin changes; no masses/cords are palpable. The thighs are symmetric, and no superficial veins are noted.

How could you determine the probability of the DVT in this patient?

What is the probability that this patient has a DVT? Modified Wells Clinical feature Score* Active cancer within 6 mo 1 Paralysis, paresis, or cast of lower extremity Recently bedridden >3 d or major surgery within 4 wk Localized tenderness along distribution of deep vein system Calf diameter >3 cm larger than opposite leg† Pitting edema Collateral superficial veins (nonvaricose) Alternative diagnosis as likely or greater than that of DVT Clinical model for predicting pretest probability for DVT *Interpretation: 0 = low probability = 3% frequency of DVT; 1-2 = medium probability= 17% frequency of DVT; ≥3 = high probability = 75% frequency of DVT. †Measured 10 cm below tibial tuberosity. -2

How would a d-dimer help? Statistically Sensitive not Specific (useful if it’s negative) High false positive rate Biomedically measures level of coagulation process in the body

Case 2 Ms. W, comes with the exact same presenting complaint and past medical history. The only difference in the presentation of Ms. W. is that she does report that she had the “flu” about one week ago and was in bed for four to five days. Additionally, her exam is significant for a swollen and tender right calf, measuring 4 cm wider in circumference than the left. There is pitting edema on the right lower extremity, extending to the inferior calf. There is no change in the skin, and no masses/cords are palpable. The thighs are symmetric, and no superficial veins are noted.

What’s the probability this patient has a DVT? 75%!! High, with wells score greater than 3

What’s the value of doing a d-dimer? If high probability 21% still positive for DVT even with negative D-dimer

What other test could you preform? Venous Doppler (venography)

Remember: the superficial femoral vein is a deep vein

Operating characteristics of diagnostic tests for proximal DVT Operating characteristics of diagnostic tests for proximal DVT* Black et al. * Diagnostic test Sensitivity, % Specificity, % Positive LR Negative LR Venography ~100 Infinity Duplex ultrasonography 95 19 0.05 Impedence plethysmography 80 16 0.21 Iodine 125 fibrinogen scan 79 62 2.1 0.34 D-Dimer level 88-100 55-80 1.9-5.0 0.4-0.02 LR = likelihood ratio.

U/S negative. End of story? With high probability clinical exam but NEGATIVE U/S: Consider other imaging, repeat study or obtain D-dimer. Consider treatment

U/S positive. Can she be treated as an outpatient? Yes Need immediate anticoagulation (i.e. Lovenox) then can bridge to warfarin No Obesity Cachetic Renal failure (GFR <40) High bleeding risk Complicated medical history Poor resources

For how long? Unprovoked 6 months? Provoked 6 months?

What’s a provoked DVT and why does it matter? Risk factors Major: Cancer, Major Surgery, Major trauma Minor: Preg., long flight, OCP, smoking, minor trauma, minor surgery

Risk of VTE recurrence after stopping anticoagulation Risk factor 1st year Next 5 years Distal DVT 3% <10% Major transient 10% Minor transient 5-6% 15% Unprovoked At least 10% 30% Recurrent >10% >30% This is why duration of therapy is based on provoked vs. unprovoked Kearon, American Society Hematology Dec. 2004

Is longer anticoagulation better in idiopathic DVT? TRIAL Duration Recurrence THRIVE 3mo 7.6/ 100pt yrs 2.1 yrs 2.6/100pt yrs PREVENT 6mo 12.6% 18 mo 2.8% PREVENT: Idiopathic DVT THRIVE Schulman et al. N Engl J Med 2003 Ridker et al. N Engl J Med. 2003

Do the experts agree with the ACCP recommendations? 8th ACCP guideline British Thoracic Society Recent recommendations First VTE, Provoked 3 months 4-6 weeks 3 months if distal or upper extremity; 6 if proximal DVT or PE Idiopathic At least 3 months, evaluate for indefinite tx Indefinite Samuel Z. Goldhaber

Should I do the thrombophilia work up?

Incidence of recurrent VTE Christensen et al. JAMA 2005. Patient group (total 474 pt) Recurrence of VTE/year With 1 thrombophilia 2.5% Initial VTE provoked 1.8% Initial VTE idiopathic 3.3% Idiopathic with thrombophilia 3.4% Idiopathic without thrombophilia 3.2% Total group 2.6% So basically having a thombophilia is much less predictive of recurrence than having an idiopathic VTE. But this is a small study that didn’t separate out the thrombophilias individually. Later they do comment that APLA does increase risk of recurrence. Based on this data, both the author of the above study and the author of a recent article in the american journal of medicine (2008) suggests that thrombophilia work up is almost never useful after a first event. They do recommend testing for APLA as it does have a significant impact on risk of recurrence.

How can I determine who’s at risk for recurrent clot? Thrombophilia Male gender Active cancer (i.e. ongoing risk factors) Recurrent dvt Proximal over distal Morbidity from DVT Repeat studies (US and ddimer)

Algorithm for Determining Duration of Treatment After 3m CHECK U/S assess bleeding risk (& discuss indefinite tx if pt with PE, Male or thrombophilia) Female: No residual clot. Clinical risk rule <1, stop AC Male: No residual clot, stop AC, measure d-dimer after 30d and stop if normal. Evidence of residual clot, continue AC and repeat U/S

REFERENCES Bates SM, Kearon C, Crowther M, et al. A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis. Annals of Internal Medicine. 2003;138(10):787-794. Black ER, Bordley DR, Tape TG, Panzer RJ. Diagnostic Strategies for Common Medical Problems. Philadelphia: American College of Physicians; 1999. Bruinstoop, E., Klok, F. A.,Van de Ree, M. A., Oosterwijk, F. L. and Huisman, M. V., Elevated d-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. Journal of Thrombosis and Haemostasis, 2009;7: 611–618 Ofri D Diagnosis and treatment of deep vein thrombosis West J Med. 2000 September; 173(3): 194–197. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, Cushman M, Moll S, Kessler CM, Elliott CG, Paulson R, Wong T, Bauer KA, Schwartz BA, Miletich JP, Bounameaux H, Glynn RJ, PREVENT Investigators N Engl J Med. 2003;348(15):1425 Rodger et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ August 26, 2008 vol. 179 no. 5 Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran.. N Engl J Med 2003 Oct 30;349:1713-21